



Original article

Treatment of Caval Vein Thrombosis Associated With Renal Tumors[☆]



Carlos Jiménez-Romero,^{a,*} María Conde,^b Federico de la Rosa,^c Alejandro Manrique,^a Jorge Calvo,^a Óscar Caso,^a Carlos Muñoz,^a Alberto Marcacuzco,^a Iago Justo^a

^a Unidad de Cirugía Hepato-Bilio-Pancreática y Trasplante de Órganos Abdominales, Hospital Universitario Doce de Octubre, Universidad Complutense de Madrid, Madrid, Spain

^b Servicio de Cirugía General, Hospital Universitario Lucus Augusti, Lugo, Spain

^c Servicio de Urología, Hospital Doce de Octubre, Madrid, Spain

ARTICLE INFO

Article history:

Received 24 September 2016

Accepted 19 January 2017

Available online 24 April 2017

Keywords:

Renal tumor

Caval thrombosis

Caval vein

Tumoral thrombus

A B S T R A C T

Introduction: Renal carcinoma represents 3% of all solid tumors and is associated with renal or inferior caval vein (IVC) thrombosis between 2% and 10% of patients, extending to right atrial in 1% of cases.

Methods: This is a retrospective study that comprises 5 patients who underwent nephrectomy and thrombectomy by laparotomy because of renal tumor with IVC thrombosis level III.

Results: Four patients were males and one was female, and the mean age was 57.2 years (range: 32–72). Most important clinical findings were hematuria, weight loss, weakness, anorexia, and pulmonary embolism. Diagnostic confirmation was performed by CT scanner. Metastatic disease was diagnosed before surgery in 3 patients. Suprahepatic caval vein and hepatic hilum (Pringle's maneuver) were clamped in 4 patients, and ligation of infrarenal caval vein was carry out in one patient.

Five patients developed mild complications (Clavien I/II). No patient died and the mean hospital stay was 8.6 days. All patients were treated with chemotherapy, and 3 died because distant metastasis, but 2 are alive, without recurrence, at 5 and 60 months, respectively.

Conclusions: Nephrectomy and thrombectomy in renal tumors with caval thrombosis can be curative in absence of metastasis or, at less, can increase survival or quality of live. Then these patients must be treated in liver transplant units because major surgical and anesthesiologic expertise. Adjuvant treatment with tyrosin kinase inhibitors must be validate in the future with wider experiences.

© 2017 AEC. Published by Elsevier España, S.L.U. All rights reserved.

[☆] Please cite this article as: Jiménez-Romero C, Conde M, de la Rosa F, Manrique A, Calvo J, Caso Ó, et al. Tratamiento de la trombosis de vena cava inferior asociada a los tumores renales. Cir Esp. 2017;95:152-159.

* Corresponding author.

E-mail address: carlos.jimenez@inforboe.es (C. Jiménez-Romero).

Tratamiento de la trombosis de vena cava inferior asociada a los tumores renales

RESUMEN

Palabras clave:

Tumor renal
Trombosis de cava
Vena cava
Trombo tumoral

Introducción: El carcinoma renal representa el 3% de los tumores sólidos y se asocia a trombosis de la vena renal o vena cava inferior (VCI) en el 2-10% de los pacientes; se extiende hasta la aurícula derecha en el 1% de los casos.

Métodos: Estudio retrospectivo de una serie de 5 enfermos intervenidos por tumor renal con trombosis tumoral de VCI de nivel III, tratados con nefrectomía y trombectomía por laparotomía.

Resultados: Cuatro de los pacientes eran hombres y uno era mujer, con una edad media de 57,2 años (rango: 32-72). Como clínica predominó la hematuria, síndrome constitucional y tromboembolia pulmonar. La confirmación diagnóstica fue por TAC. En 3 pacientes se detectaron metástasis antes de la cirugía. Se realizó Pringle y pinzamiento de vena cava suprahepática en 4 pacientes y ligadura de VCI infrarrenal en uno.

Complicaciones leves (Clavien I/II) se presentaron en 5 pacientes. La mortalidad fue nula y la estancia hospitalaria media fue de 8,6 días. Todos los pacientes se trataron con quimioterapia; fallecieron 3 por metástasis a distancia, permanecen 2 vivos, sin recidiva, a los 5 y 60 meses. Supervivencia media: 26,6 meses.

Conclusiones: La nefrectomía y la trombectomía en tumores renales con trombosis de cava pueden ser curativas en ausencia de metástasis o, al menos, pueden aumentar la supervivencia y mejorar la calidad de vida. Para ello estos pacientes deberían tratarse en unidades de trasplante hepático por su mayor experiencia quirúrgica y anestésica. El tratamiento adyuvante con inhibidores de la tirosina cinasa debe validarse en el futuro con experiencias más amplias.

© 2017 AEC. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Renal cell carcinomas represent 3% of solid tumors.¹ They cause a thrombus in the renal vein or inferior vena cava (IVC) in 2-10% of patients,^{2,3} and the thrombus extends to the right atrium in 1% of cases.² The treatment indicated in these patients involves nephrectomy and thrombectomy of the cava, although this surgery also presents morbidity and mortality. In order to reduce these complications, it is necessary to identify and adequately expose the vena cava, liver and retroperitoneum in conjunction with the Urology Department in order to conduct the nephrectomy. Before surgery, it is essential to define the exact location of the thrombus in the cava to plan the best possible surgical approach. Depending on the location of the thrombus in the IVC, different techniques have been used, such as laparotomy,⁴⁻⁶ assisted laparoscopy,⁷ venovenous bypass⁸ or cardiopulmonary bypass with mild hypothermia.⁹ In this study, we present our experience in the treatment of three tumors by laparotomy.

Methods

We present a retrospective study of patients with renal tumor and thrombosis of the inferior vena cava that had been treated surgically between 2011 and 2016 by our HBP Surgery and Abdominal Organ Transplantation Units in collaboration with the Urology Department. The objective of this case series is to

explain the symptoms, diagnosis and surgical techniques performed to locate the thrombus, as well as to analyze perioperative morbidity and mortality.

This series includes 5 patients, for whom demographic, preoperative, intraoperative and postoperative variables (Clavien et al. classification¹⁰), histological characteristics and survival were collected and analyzed. The classification adopted was the Ciancio et al. classification,¹¹ which is based on the extension or invasion of the thrombus in the IVC (Table 1, Fig. 1). Out of the 5 cases, one corresponded with level IIIa, 3 IIIb and one IIIc. The radiological diagnosis was reached with ultrasound and CT in all cases, which demonstrated the level of invasion of the thrombus in the IVC (Fig. 2).

Table 1 – Classification of IVC Thrombosis Levels.

I Thrombus limited to the renal vein
II Thrombus in infrahepatic IVC
III Thrombus in retrohepatic IVC
a) Thrombus in retrohepatic IVC, under the suprahepatic veins
b) Thrombus in retrohepatic IVC in contact with the orifice of the suprahepatic veins
c) Thrombus in the retrohepatic IVC, above the suprahepatic veins but under the diaphragm
d) Thrombus in the suprahepatic and supradiaphragmatic IVC, reaching the intrapericardial IVC, although subatrial
IV Thrombus in the right atrium

Source: from Ciancio et al.¹¹




Fig. 1 - Classification of thrombosis of the inferior vena cava (according to Ciancio et al.¹¹).

As for the surgical technique (except for level IIIa), in cases where the thrombus was proximal to the suprahepatic veins, intraoperative transesophageal echocardiogram was used to evaluate the mobility of the thrombus during surgery. We used an inverted T incision in 3 patients and a Mercedes in the remaining 2, which are standard incisions in liver transplantation. In all cases, we used a Stieber rib grip to widely separate the rib edge upwards, which allowed us to comfortably carry out the dissection of the liver and IVC. Renal tumors, especially large ones, present infiltration, firm adhesions and displacement of other organs (duodenum-pancreas, colon-hepatic angle and hepatic hilum in case 1, colon-hepatic angle in case 2 and tail of the pancreas in case 5). Initially, we freed the posterolateral side of the kidney using a posterior approach to identify, ligate and divide the renal artery, reducing collateral circulation and facilitating renal dissection.

Liver mobilization is performed similarly to liver transplantation: ligation and division of the round ligament; division with electrocoagulation of the falciform ligament, coronary and triangular ligaments, both on the right as well as the left, as well as the hepatorenal ligament. The liver pedicle is surrounded with a vascular loop for a possible Pringle maneuver. Dissection, ligation and division of the retrohepatic veins (piggy-back technique) are completed to expose the IVC and its entire extension, below the suprahepatic veins. The suprahepatic IVC is dissected and surrounded by a vascular loop for potential posterior clamping. This dissection provides

for resolution of all cases of levels IIIa and IIIb IVC thrombosis, performing suprahepatic or infrahepatic clamping (below the suprahepatic veins) and clamping below the thrombus, usually at the infrarenal level. If the piggy-back is not complete (without dissection of retrohepatic veins of the caudate lobe), the suprahepatic IVC is clamped at levels IIIa and IIIb for 10-15 min along, accompanied by a Pringle maneuver of equal duration. At level IIIc, we performed the same dissection, but "milked" the thrombus caudally before clamping the suprahepatic IVC.

Although we do not present any cases, at levels IIIc (intrapercardial IVC thrombus) or IV (as long as the thrombus is not adhered to the atrium), the thrombus can be removed abdominally, as in previous levels, by infrahepatic cavotomy with previous diaphragmatic incision, intrapericardial dissection of the IVC, and milking the thrombus with the fingers until it surpasses the infrahepatic IVC, at which time it is clamped at this level above the thrombus.

Once this dissection is performed, we place the patient in Trendelenburg position, clamp the infrarenal IVC (below the thrombus) and the renal vein affected by the thrombus, the contralateral renal vein and the IVC above the thrombus of the cava (at the infrahepatic level, if we have performed a complete piggy-back, or at the suprahepatic level supplemented with a Pringle maneuver if it is incomplete). At this time, we perform a longitudinal cavotomy measuring 3-5 cm and extract the thrombus with the index finger, washing afterwards with heparinized saline. A longitudinal continuous




Fig. 2 – Renal tumors with thrombosis of the inferior vena cava (cases 1, 2, 4 and 5) with levels IIIa, IIIb and IIIc, according to the Ciancio et al. classification.¹¹

suture of the IVC is then carried out with 4-5/0 polypropylene. Before making the last stitch, we release the infrarenal IVC and the contralateral renal vein to eliminate thrombi and air, and then fill with blood the lumen of the IVC previously occupied by the thrombus. Simultaneously, the Pringle and IVC clamps are removed above the thrombus. The renal vein affected by the tumor thrombosis is divided at its union with the IVC, thereby impeding a residual tumor thrombus from remaining in the stump, and the nephrectomy is then completed (Figs. 3 and 4).

In our case 4 with level IIIb thrombosis, a soft thrombus was also detected, which began 3 cm below the renal veins and reached the iliac veins. In these cases, important chronic collateral circulation develops, in such a way that the gonadal vein and the lumbar branches connect with the azygos and hemiazygos system to reach the right atrium. Thus, after the aforementioned cava thrombectomy, we double-ligated the infrarenal IVC with silk 1-0 above the soft thrombus to prevent its migration toward the atrium. The mentioned collateral veins should not be ligated so as not to compromise the venous return toward the atrium. Proper anesthetic management of these patients is also very important by anesthesiologists with experience in liver transplantation.

Results

Out of this series of 5 patients, 4 were men and one was a woman, with a mean age of 57.2 years (range: 32–72).

Predominant symptoms included hematuria, weight loss and pulmonary thromboembolism (PTE). In all cases, ultrasound was performed as the first diagnostic test, followed by CT scan for confirmation (PET/CT in one patient). In 3 patients, pulmonary, hepatic, bone or cerebral metastases were detected before surgery.

Clamping of the suprahepatic IVC and Pringle maneuver (10–15 min) was performed in 4 patients, while in the first case (level IIIa) clamping was done under the suprahepatic veins. The infrarenal IVC was clamped (below the thrombus) in all cases for 10–15 min. Definitive silk ligation of the infrarenal IVC above the soft thrombus, after thrombectomy of the main thrombus, was performed in one patient. Mean surgical time for nephrectomy and thrombectomy was 334 min (range: 240–400), and mean transfusion of packed red blood cells was 6.4 units.

The primitive tumor was located in the right kidney in 4 cases and in the left in one, with a size of 5–20 cm. In 4 patients, the tumor was comprised of club cells, while the other was a Ewing tumor. Tumor cells were isolated in the cava thrombus in all patients, whereas the adrenal gland showed no tumor invasion in any of the cases.

Postoperative complications were minor in all patients (Clavien I in 3 and Clavien II in 2), with an average hospital stay of 8.6 days. Out of the 5 patients, 4 were treated with chemotherapy (one currently in treatment), and radiotherapy was added to the patient with renal Ewing's sarcoma. Two patients survived to 60 months, and the last patient treated to 5 months; the remaining 3 died of metastatic




Fig. 3 – (A) Dissection of the suprahepatic vena cava; (B) piggy-back and dissection of the renal veins and infrarenal vena cava; (C) cavotomy and extraction of the thrombus; (D) cavography.




Fig. 4 – (A) Right renal tumor with thrombosis of the cava (IIIb); and (B) left renal tumor with thrombosis of the cava (IIIc).

disease at 11, 18 and 39 months, with a mean survival of 26.6 months (Table 2).

Discussion

In the Memorial series,³ 82% of patients with renal tumor and IVC thrombosis were symptomatic at the time of diagnosis, and

19% had distant metastases. On the other hand, in the Mayo Clinic series,¹² about 40% of these patients with renal tumor and IVC thrombosis presented metastases at the time of surgery: 28.5% at a distance and 11.7% of the regional lymph nodes.

In our short series, taking into account that all patients presented level III thrombosis, 80% showed symptoms (mainly constitutional syndrome, hematuria and PTE), and 60% had distant metastases at the time of diagnosis.

Table 2 – Renal Tumors With Vena Cava Thrombosis.

	1	2	3	4	5
Sex	Male	Female	Male	Male	Male
Age (yrs)	32	69	69	44	72
Symptoms	Varicocele, hematuria	Constitutional synd., hematuria	Constitutional synd., hematuria, PTE, edemas of lower limbs	Constitutional synd., pain, PTE	Asymptomatic
<i>Preoperative</i>					
ASA classification	I	III	III	III	III
Imaging studies	Ultrasound + CT	Ultrasound + CT	Ultrasound + PET-CT	Ultrasound + CT	Ultrasound + CT
Preoperative TNM	T3bN0M0	T3bN0M1	T3bN0M1	T3bN0M1	T3bN0M0
Hb (g/dL)	13.8	8.4	14.1	11	11.7
Platelets	305 000	256 000	310 000	306 000	377 000
<i>Intraoperative</i>					
Laparotomic incision	Mercedes	Mercedes	Inverted T	Inverted T	Inverted T
Type of thrombus (classif.)	IIIa	IIIb	IIIb	IIIb	IIIc
Suprahepatic IVC clamping	No	Yes	Yes	Yes	Yes
Pringle clamping (min)	No	10	12	15	10
Infrarenal IVC clamping (min)	11	10	12	15	10
Length of cavotomy (cm)	3	4	5	5	5
Ligature/infrarenal cava division	No	No	No	Yes	No
Nephrectomy	Right	Right	Right	Right	Left
Surgical time (min)	240	340	330	400	360
Transfusion (erythrocytes)	5	6	6	5	5
Transfusion FFP (U)	4	4	No	4	4
Vasoactive agents	No	Yes	No	Yes	Yes
<i>Postoperative</i>					
Complications (Clavien)	I	II	I	II	I
Hospital stay (days)	7	6	8	15	7
<i>Renal tumor</i>					
Size (cm)	20	10	7.5	9	5
TNM classification:	pT4NxMx	pT3bN0Mx	pT3bN0Mx	pT3bN0Mx	pT3bN0Mx
Histological type	PNET (Ewing)	Club cells	Club cells	Club cells	Club cells
Fuhrman classification	-	3	3	3	2
Tumor cells in thrombus	Yes	Yes	Yes	Yes	Yes
Tumor cells in adrenal gland	No	No	No	No	No
<i>Follow-up</i>					
Adjuvant treatment	VAC/CHOP + IFO/VP16 RT _x (4500 Gy)	Sunitinib (50 mg/day) (1 month)	Sunitinib (50 mg/day)	Pazopanib (800 mg/day)	Axitinib
Cause of death	No	Metastases in lung, brain	Metastases in lung, bones, liver	Metastases in lung, bones, liver	No
Survival (months)	60 (disease-free)	39	11	18	5
Current status	Living	Deceased	Deceased	Deceased	Living

FFP: fresh frozen plasma; RT_x: radiotherapy; PTE: pulmonary thromboembolism; PNET: primitive neuroectodermal tumor; TNM: tumor node metastasis; IVC: inferior vena cava.

The diagnosis of an IVC thrombus is confirmed with magnetic resonance imaging, which is especially useful for detecting a soft thrombus in the infrarenal IVC,¹³ or by multi-slice CT scan.¹⁴

Level I or II IVC thrombi are treated by dissection of the IVC, without the need for a complete piggy-back, with clamping of the contralateral renal vein and the IVC above and below the thrombus, followed by cavotomy and thrombectomy.

It has been demonstrated that, in cases of level III IVC thrombi, thrombectomy can be performed without using bypass techniques, thereby basically avoiding neurological, pulmonary, or coagulopathy complications.^{3,4,10} In level IV thrombosis, venovenous or cardiopulmonary bypass can be avoided if the thrombus is free (not adhered to the atrium) using the intraabdominal approach, followed by division of

the diaphragm. Thus, the intrapericardial IVC and right atrium are controlled, and the thrombus is “milked” with the fingers toward the IVC below the suprahepatic veins.¹⁵

If ligation and division of all retrohepatic veins or the piggy-back technique are used as in liver transplantation, it is not necessary to clamp the hepatic hilum in level III thrombosis prior to thrombectomy.¹⁵ Alternatively, in our experience, in levels I, II and III it is not necessary for the piggy-back to be complete if we clamp the hepatic hilum (Pringle maneuver) and the suprahepatic IVC for 10–15 min, which is sufficient time to perform the 3–5 cm cavotomy, thrombectomy and suture of the vena cava.

In the rarest case of thrombosis with complete IVC obstruction associated with an infrarenal soft thrombus reaching up to the iliac veins, collateral circulation formed

through the lumbar veins that drain the system of the azygos and hemiazygos veins. Here, thrombectomy of the formed thrombus should be done with ligation or division with a stapler of the IVC above the soft thrombus, which is left intact to prevent its mobilization toward the atrium.¹⁶

It has been observed that the higher the level of the thrombus, the greater the need for blood transfusion during surgery.^{3,15} Two American series report between 4.3 and 4.7 units of transfused packed red blood cells,^{3,15} while the mean number of units transfused in our patients was 5.4. The reported average surgical time has been between 250 and 467 min,^{3,12,15} while the mean was 334 min in our patients.

In our series, we have observed the presence of tumor cells in all the cava thrombi but the absence of these cells in the adrenal gland excised together with the renal tumor.

In the series of 77 patients at Memorial,³ which considered all levels of thrombosis, the incidence of major complications was 36% and minor complications 18%. Hemorrhage and PTE are serious complications associated with the higher level of cranial extension of the thrombus.¹⁷ Our patients have only presented minor complications (Clavien I or II). According to different series,^{3,6,12} perioperative mortality was 3.5–6%, which was null in our experience. Mean reported hospital stay was between 7 and 9 days^{12,15} and 8.6 days in our series.

The higher the level of the thrombus, the more advanced the tumor stage,^{3,15} and median survival decreases.^{18,19} Independent factors of poor prognosis include the presence of metastasis at the time of diagnosis and non-club cell renal tumors.⁶ There is controversy regarding radical surgery in cases of renal tumors with distant metastases and cava thrombosis: some authors state that the possibility of increased survival is not justified by the high morbidity and mortality associated with surgery.²⁰ However, recently, other authors have demonstrated the absence of differences in morbidity and mortality rates, whether or not there is distant metastasis.²¹

After surgery, 5-year survival is 15–20% with regional or distant metastases and only 4% with both types of metastases. In cases with no metastasis, survival reaches 60%.¹² However, even in patients with distant metastases, surgery is still indicated as it increases survival and improves quality of life.^{15,22–24} In patients with distant metastases, mean survival rates of 13 months and 2-year survivals of 26% have been reported.²⁵ In general, nephrectomy and thrombectomy are associated with greater survival than conservative treatment in cases of renal tumors with IVC thrombosis (19.8 months versus 6.9 months).¹⁸ Another series confirms that the mean survival of patients who are not treated surgically is only 5 months.²⁶ Surgical treatment of metastatic lesions can be performed simultaneously with the renal surgery or at a later stage, depending on the patient's condition. Thus, surgical rescue of a metachronous lesion is considered when it is a single lesion in a patient in good general condition.²⁷

Recently, several series have reported patients treated by laparoscopy²⁸ or robotic surgery,^{29,30} with results similar to those obtained by laparotomy.

Several cases of neoadjuvant therapy with sunitinib have been reported, in which level IV thrombi have been reduced in size.³¹ Initial treatment with tyrosine-kinase inhibitors (sunitinib, pazopanib, axitinib) should be considered for its

potential in both infra-staging as well as the reduction of postoperative morbidity.³²

We conclude that nephrectomy and thrombectomy in renal tumors with cava thrombosis may be a curative technique in the absence of metastasis or may at least increase survival and improve quality of life. These patients should be treated in liver transplantation units due to their greater surgical and anesthetic experience. In the future, adjuvant treatment with tyrosine-kinase inhibitors should be validated with more extensive studies.

Authorship/Collaborators

- Carlos Jiménez-Romero: study design; composition of the article.
- María Conde: data collection; composition of the article.
- Federico de la Rosa: data collection; analysis and interpretation of the results.
- Alejandro Manrique: analysis and interpretation of the results; critical review and approval of the final version.
- Jorge Calvo: data collection; analysis and interpretation of the results.
- Óscar Caso: data collection; analysis and interpretation of the results.
- Carlos Muñoz: data collection; analysis and interpretation of the results.
- Alberto Marcacuzco: data collection; critical review and approval of the final version.
- Iago Justo: critical review and approval of the final version; study design.

Conflict of Interests

The authors have no conflict of interests to declare.

REFERENCES

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. *CA Cancer J Clin.* 2010;60:277–300.
2. Marshall VF, Middleton RG, Holswade GR, Goldsmith EI. Surgery for renal cell carcinoma in the vena cava. *J Urol.* 1970;103:414–20.
3. Kaag MG, Toyen C, Russo P, Cronin A, Thompson RH, Schiff J, et al. Radical nephrectomy with vena caval thrombectomy: a contemporary experience. *BJU Int.* 2010;107:1386–93.
4. Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. *BJU Int.* 2004;94:33–41.
5. Parekh DP, Cookson MS, Chapman W, Harrell F, Wells N, Chang SS. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features surgical techniques and outcomes. *J Urol.* 2005;173:1897–902.
6. Ciancio G, Manoharan M, Katkooi D, de los Santos R, Soloway MS. Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombosis: single center experience. *Eur Urol.* 2010;57:667–72.

7. Henderson A, Murphy D, Jaganathan K, Roberts WW, Wolf JS Jr, Rané A, et al. Hand-assisted laparoscopic nephrectomy for renal cell cancer with renal vein tumor thrombus. *Urology*. 2008;72:268-72.
8. Granberg CF, Boorjian SA, Schaff HV, Orszulak TA, Leibovich BC, Lohse CM, et al. Surgical management complications and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass. *Urology*. 2008;72:148-52.
9. Chowdhury UK, Mishra AK, Seth A, Dogra PN, Honnakere JHV, Subramaniam GK, et al. Novel techniques for tumor thrombectomy for renal cell carcinoma with intraatrial tumor thrombus. *Ann Thorac Surg*. 2007;83:1731-6.
10. Clavien P, Sanabria J, Strasberg S. Proposed classification of complications of surgery with examples of utility in cholecystectomy. *Surgery*. 1992;111:518-26.
11. Ciancio G, Vaidya A, Savoie M, Soloway M. Management of renal cell carcinoma with level III thrombus in the inferior vena cava. *J Urol*. 2002;168:1374-7.
12. Boorjian S, Sengupta S, Blute M. Renal cell carcinoma: vena caval involvement. *BJU Int*. 2007;99:1239-44.
13. Oto A, Herts BR, Remer EM, Novick AC. Inferior vena cava tumor thrombus in renal cell carcinoma: staging by MR imaging and impact on surgical treatment. *Am J Roentgenol*. 1998;171:1619-24.
14. Guzzo TJ, Pierorazio PM, Schaeffer EM, Fishman EK, Allaf ME. The accuracy of multidetector computerized tomography for evaluating tumor thrombus in patients with renal cell carcinoma. *J Urol*. 2009;181:486-91.
15. Ciancio G, Soloway MS. Renal cell carcinoma with tumor thrombus extending above diaphragm: avoiding cardiopulmonary bypass. *Urology*. 2005;66:266-70.
16. Blute ML, Boorjian SA, Leibovich BC, Lohse CM, Frank I, Karnes J. Results of inferior vena cava interruption by Greenfield filter ligation or resection during radical nephrectomy and tumor thrombectomy. *J Urol*. 2007;178:440-5.
17. Kown TW, Kim H, Moon KM, Cho YP, Song C, Kim CS, et al. Surgical treatment of inferior vena cava tumor thrombus in patients with renal cell carcinoma. *J Korean Med Sci*. 2010;25:104-9.
18. Haferkamp A, Bastian PJ, Jakobi H, Pritsch M, Pfitzenmaier J, Albers P, et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term follow-up. *J Urol*. 2007;177:1703-8.
19. Klaver S, Joniau S, Suy R, Oyen R, van Poppel H. Analysis of renal cell carcinoma with subdiaphragmatic macroscopic venous invasion (T3b). *BJU Int*. 2007;101:444-9.
20. Swierzewski DJ, Swierzewski MJ, Libertino JA. Radical nephrectomy in patients with renal cell carcinoma with venous vena caval and auricular extension. *Am J Surg*. 1994;168:205-9.
21. Lambert EH, Pierorazio PM, Shabsigh A, Olsson CA, Benson MC, McKiernan JM. Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. *Urology*. 2007;69:1054-8.
22. Bromwich E, Hendry D, Aitchinson M. Cytoreductive nephrectomy: is a realistic option in patients with renal cancer? *BJU Int*. 2002;89:523-5.
23. Goetzl MA, Goluboff ET, Murphy AM, Katz AE, Mansukhani M, Sawczuk IS, et al. A contemporary evaluation of cytoreductive nephrectomy with tumor thrombus: morbidity and long-term survival. *Urol Oncol*. 2004;22:182-7.
24. Kirkali Z, van Poppel H. A critical analysis of surgery for kidney cancer with vena cava invasion. *Eur Urol*. 2007;52:658-62.
25. Staehler G, Brkovic D. The role of radical surgery for renal cell carcinoma with extension into the vena cava. *J Urol*. 2000;163:1671-5.
26. Reese AC, Whitson JM, Meng MV. Natural history of untreated renal cell carcinoma with venous tumor thrombus. *Urol Oncol*. 2013;31:1305-9.
27. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofman, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. *Eur Urol*. 2015;67:913-24.
28. Lue K, Russell CM, Fisher J, Kurian T, Agarwal G, Luchey A, et al. Predictors of postoperative complications in patients who undergo radical nephrectomy and IVC thrombectomy: a large contemporary tertiary center analysis. *Clin Genitourin Cancer*. 2016;14:89-95.
29. Shao, Li J, Qin C, Lv Q, Ju X, Li P, et al. Laparoscopic radical nephrectomy and inferior vena cava thrombectomy in the treatment of renal cell carcinoma. *Eur Urol*. 2016;68:115-22.
30. Gill IS, Metcalfe C, Abreu A, Duddalwar V, Chopra S, Cunningham M, et al. Robotic level III vena cava tumor thrombectomy: initial series. *J Urol*. 2015;194:929-38.
31. Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ, et al. Neoadjuvant sunitinib induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. *Eur Urol*. 2008;53:845-8.
32. Di Lorenzo G, Autorino R, Sternberg CN. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. *Eur Urol*. 2009;56:959-71.